1 Kearns GL.Impact of developmental pharmacology on pediatric study design :overcoming the challenges[J].J Allergy Clin Immunol, 2000;106(3):S128-38
2 Ittmann PI, Amarnath RA, Berseth CL.Maturation of antroduodenal motor activity in preterm and term infants[J].Dig Dis Sci, 1992;37(1):14-9
3 van Lingen RA, Deinum JT, Quak JM, Kuizenga AJ, van Dam JG, Anand KJ, et al.Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates[J].Arch Dis Child Fetal Neonatal Ed, 1999;80(1):F59-63
4 Lin JH, YamazakiM.Role of P-glycoprotein in pharmacokinetics:clinical implications[J].Clin Pharmacokinet, 2003;42(1):59-98
5 Tsai C, Ahdab-Barmada M, Daood MJ, Watchko JF.P-glycoprotein expression in the developing human central nervous system :cellular and tissue localization[J].Pediatr Res, 2001;47:436A
6 Chen H, Fantel AG, Juchau MR.Catalysis of the 4-hydroxylation of retinoic acids by CYP3A7 in human fetal hepatic tissues[J].Drug Metab Dispos, 2000;28(9):1051-7
7 Sonnier M, Cresteil T.Delayed ontogenesis of CYP1A2 in the human liver[J].Eur J Biochem, 1998;251(3):893-8
8 Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, et al.Human liver carbamazepine metabolism : role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation[J].Biochem Pharmacol, 1994;47(11):1969-79
9 Bajpai M, Roskos LK, Shen DD, Levy RH.Rules of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite[J].Drug Metab Dispos, 1996;24(12):1401-3
10 Kraus DM, Fischer JH, Reitz SJ, Kecskes SA, Yeh TF, Mc-Culloch KM, et al.Alterations in theophylline metabolism during the first year of life[J].Clin Pharmacol Ther, 1993;54(4):351-9
11 Takahashi H, Ishikawa S, Nomoto S, Nishigaki Y, Ando F, Kashima T, et al.Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children[J].Clin Pharmacol Ther, 2000;68(5):541-55
12 Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. Liver volume as a determinant of drug clearance in children and adolescents[J].Drug Metab Dispos, 1995;23(10):1110-6
13 Scott CS, Riggs KW, Ling EW, Fitzgerald CE, Hill ML, Grunau RV, et al.Morphine pharmacokinetics and pain assessment in premature newborns[J].J Pediatr, 1999;135(4):423-9
14 James LP, Marotti T, Stowe CD, Farrar HC, Taylor BJ, Kearns GL, et al.Pharmacokinetics and pharmacodynamics of famotidine in infants[J].J Clin Pharmacol, 1998;38(12):1089-95
15 Van den Anker JN, Hop WC, de Groot R, van der Heijden BJ, Broerse HM, indemans JL, et al.Effects of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant[J].Pediatr Res, 1994;36(5):578-81
16 Gregory LK, Susan MA, Sarah WA, Douglas LB, Steven L, Ralph EK. Developmental pharmacology-drug disposition, action, and therapy in infants and children[J].N Engl J Med,2003;49(12):1157-67
17 Kearns GL.A method to approximate the initial drug dose for an infant[A].In :Ritschel WA, Kearns GL, eds.Handbook of basic pharmacokinetics-including clinical applications [M].5th edition .Washington D.C.:American Pharmaceutical,1999:318-9
18 Steinbrook R.Testing medications in children[J].N Engl J Med, 2002;347(18):1462-70
19 Kauffman RE.Clinical trials in children:problems and pitfalls[J].Paediatr Drugs, 2000;2(6):411-8
20 Leeder JS, Kearns GL.The challenges of delivering pharmacogenomics
21 into clinical pediatrics[J].Pharmacogenomics J,2002;2(3):141-3 |
